TrialBlood cancer journal2016

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

A Bühler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.